Note: This is an archived post, and EMPowerplus has been the subject of several other studies since publication. You can read about all Truehope research here.
Truehope is in the news again.
Not only do we produce the most-researched micronutrient formula in history, but we just reached a major milestone: 20 studies. That’s right, we’ve finally reached 20 studies that confirm the efficacy of EMPowerplus in providing nutritional support for mental and physical well-being.
Our most recent study was conducted by a group of researchers at the University of Calgary and the Center for Integrative Psychiatry in The Netherlands, and it was published in BMC Case Reports just last week.
The researchers studied the results of 6 months of inpatient care for an 11-year-old boy who was being treated for Psychosis—NOS, OCD, borderline intellectual functioning, paediatric autoimmune neuropsychiatric disorders associated with Strep, generalized anxiety disorder, and social anxiety disorder. Then they studied the results of 6 months of outpatient care while he was taking EMPowerplus, our flagship product of 36 vitamins, minerals, amino acids, and antioxidants.
When the boy left inpatient care, his score on the Children’s Global Assessment Scale was 35, the same score he had when entering treatment six months earlier. His score remained unchanged despite receiving various medications (including quetiapine, risperidone, fluoxetine, fluvoxamine, and clonazepam); assessment or treatment from at least four child/adolescent psychiatrists; and consultation from a paediatric neurologist.
After starting EMPowerplus, the boy was medication-free after only 1 month. In addition, his psychosis symptoms resolved, his anxiety-related symptoms abated, and all diagnoses were fully remitted by 14 months. When he was discharged from outpatient care, his CGAS had doubled to 70, and he has not required further mental health treatment for over 3 years.
In addition, researchers compared the cost of his inpatient care with the cost of his outpatient care. Six months of inpatient care cost nearly $160,000, while six months of outpatient care as an EMPowerplus participant cost nearly $3000. The conventional treatment route cost about 55 times that of the second route and saw virtually no improvement in symptoms.
This new research brings our total to 20 studies done on EMPowerplus by 39 independent researchers at 14 universities around the world. And there are still more on the way.